London · Delayed Price · Currency is GBP · Price in SEK Xspray Pharma AB Company Description
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden.
The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers.
It has partnership agreements with EVERSANA for the commercialization of Dasynoc, as well as with NerPharMa S.r.l for production of Dasynoc.
The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017.
Xspray Pharma AB (publ) was incorporated in 2003 and is headquartered in Solna, Sweden.
| Country | Sweden |
| Founded | 2003 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 26 |
| CEO | Per Andersson |
Contact Details
Address: Scheeles väg 2 Solna, 171 65 Sweden | |
| Phone | 46 87 30 37 00 |
| Website | xspraypharma.com |
Stock Details
| Ticker Symbol | 0GHZ |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Per Andersson Ph.D. | Chief Executive Officer |
| Dr. Mustafa Demirbüker Ph.D. | Co-Founder and Science Director |
| Kerstin Hasselgren | Chief Finance Officer |
| Gérald Jesson | Vice President of Operations |
| Dr. Helene Dérand Ph.D. | Sales and Marketing Director |
| Charlotta Liljebris | Head of Research & Development |